View abstract

Cet abstract a été assigné à session BGS: Belgian Glaucoma Society
TitrePfizer award: The effect of atorvastatin (Lipitor®) on intraocular pressure and ocular blood flow in patients with glaucoma
ButStatins are known to have pleiotropic effects, such as the improvement of endothelium-dependent relaxation by stimulating the nitric oxide signal pathway. Long-term statin therapy may contribute to a reduced risk of age-related macular degeneration, diabetic retinopathy, and glaucoma, all ocular disorders thought to be associated with impaired ocular circulation. A recent small-scale study indicated that systemic administration of simvastatin (Zocor°) for seven days in healthy volunteers decreased intraocular pressure (IOP), and increased blood flow velocity in the retinal arteries and veins whereas the diameter of the retinal vessels was unchanged.
MéthodesThis prospective, double-masked, placebo-controlled study is designed to evaluate the effect of atorvastatin (Lipitor°) versus placebo on IOP and retrobulbar blood flow velocities in 20 patients with open angle glaucoma (OAG) or normal tension glaucoma (NTG). Blood flow velocities will be measured in the retrobulbar vessels using color Doppler imaging. After the baseline visit, the patient will be instructed to take atorvastatin 80mg 1x/d in the morning, and will be re-examined after 7 days (second study visit) and 3 months (third study visit).
ConclusionWe hypothesize that atorvastatin may reduce IOP as well as increasing ocular blood flow in patients with glaucoma. Therefore, Atorvastatin might be a useful drug in the management of glaucoma.
Auteur 1
NomSTALMANS
InitialesI
InstitutUniversity Hospitals Leuven
VilleLeuven
top ^